Board of directors
Søren Elmann Ingerslev
Mr. Elmann Ingerslev is an attorney at law and partner in the Danish law firm Elmann Advokatpartnerselskab. Mr. Ingerslev has extensive experience in company strategy and acquisitions. Mr. Ingerslev was previously with the Danish law firms Bech-Bruun and Abel & Skovgård Larsen with responsibility for mergers/acquisitions, company law and international business agreements. Mr. Ingerslev currently serves as a non-executive member of the board of directors at several companies.
Ms. Sebree is an experienced pharmaceutical and biotechnology entrepreneur who has successfully founded, financed, grown, and taken public three biopharmaceutical companies. Ms. Sebree is currently President of Zynerba Pharmaceuticals (Nasdaq: ZYNE) based in Devon, PA, USA. Ms. Sebree co-founded NuPathe Inc. (Nasdaq: PATH) and served as President from February 2005 to March 2014. Prior to NuPathe, Ms. Sebree served as Senior Vice President, Development of Auxilium Pharmaceuticals (Nasdaq: AUXL) from January 2000 to January 2005. Prior to joining Auxilium, Ms. Sebree served as Executive Vice President, United States Operations at IBAH, Inc., a contract research organization. Previously, Ms. Sebree served in a variety of management roles with Abbott Laboratories for over nine years including its development head for psychopharmacology products. Ms. Sebree holds a BS from Texas A&M University.
Viggo G. Harboe
Mr. Viggo G. Harboe joined DAKO A/S (today part of Aglient Technologies, Inc.) in 1972. In 1980 Mr. Viggo G. Harboe founded DAKO’s first subsidary in the USA. He served as CEO in USA until 2002. Mr. Viggo G. Harboe also founded DAKO’s subsidiaries in Japan, Australia and Canada and served on the Board of these. Mr. Viggo G. Harboe was member of the Board of Directors at DAKO from 2002 to 2007 when the company was sold. Mr. Viggo G. Harboe served as Chairman of the Harboefoundation from 2002 to 2019.